Küçük Hücre Dışı Akciğer Kanserlerinin Tanısında, Tedaviye Yanıt ve Prognoz Tayininde KIAA1522 Ekspresyonunun Değerlendirilmesi
Özet
Non-small cell lung cancer accounts for more than 85% of incidences of lung cancer and is one of the most fatal cancers. Novel lung cancer biomarkers are needed for non-small cell lung cancers for which the predicted survival rate about 15.9% and less than a year in those with metastatic disease. A recent prospective study revealed that high expression of KIAA1522 was significantly associated with poor prognosis and decreased overall survival. We identified 98 patients who underwent radical curative surgical resections and metastatectomies for pulmonary adenocarcinoma and squamous cell carcinoma at our institution or the pathological diagnosis confirmed by our pathologists. In accordance with recent data, we evaluated KIAA1522 expression by immunohistochemistry and its association with clinicodemographic parameters, pathological stages, recurrence rates, overall survival and disease-free survival of the patients in whom complete remission had been achieved. Expression profiles in samples with adenocarcinoma was not significantly different from samples with squamous cell carcinoma (p: 0.6). Survival analysis was performed with log-rank tests and multivariate Cox proportional hazard model. High KIAA1522 expression was observed 54 out of 98 samples (55.1%) and patients with high KIAA1522 expression has a significantly shorter overall survival in comparison with low expression group (p: 0.01). Multivariate Cox proportional hazard analyses revealed that among with age groups (≥60 versus <60), TNM stage, ECOG performance status; high expression of KIAA1522 was an independent prognostic factor; particularly for those whom had metastatic disease(HR 2.427, p: 0.022, 95% CI [1.140-5.168]). High expression profile did not seem to be significantly associated with disease-free survival in those whom complete remission had been achieved, but those patients with high expression of KIAA1522 tended to exhibit a shorter disease-free survival rate (p: 0.12). As a result, it can be suggested that KIAA1522 expression is an independent factor for predicting overall survival and may serve as a prognotsic indicator for relapse and disease-free survival.
